BioMarin nabs Genentech exec to be its CEO

3 November 2023

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) announced that Alexander Hardy has been named as the company’s president and chief executive.

He will succeed Jean-Jacques Bienaimé, who will retire as chairman and CEO effective December 1, 2023. Mr Hardy, currently the CEO of Genentech, the US biotech subsidiary of Swiss pharma giant Roche (ROG: SIX), will also serve as a director on BioMarin's board of directors. Richard Meier, BioMarin's lead independent director, will assume the role of chairman of the board of directors.

Mr Hardy brings more than 30 years of experience in the global healthcare and biotechnology industries, most recently at Genentech, where he has served as CEO since 2019 and during his tenure demonstrated the ability to deliver growth during a particularly challenging period in which the company lost exclusivity of three of its biggest products. In this most recent role at Genentech, the organization has launched more than 10 new medicines and achieved leading positions across oncology, neuroscience, hemophilia and ophthalmology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK